| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,450,000 |
| Market
Cap: |
1.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$17.98 - $30.33 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
541,184 |
604,610 |
1,126,332 |
1,350,628 |
| Total Sell Value |
$14,612,172 |
$15,873,366 |
$28,813,301 |
$33,344,509 |
| Total People Sold |
7 |
7 |
7 |
7 |
| Total Sell Transactions |
32 |
36 |
53 |
67 |
| End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Quart Barry D |
|
– • – |
2025-06-11 |
4 |
S |
$30.39 |
$374,891 |
D/D |
(12,336) |
12,546 |
|
6% |
|
| Quart Barry D |
|
– • – |
2025-06-11 |
4 |
OE |
$3.80 |
$46,877 |
D/D |
12,336 |
24,882 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-11 |
4 |
AS |
$30.51 |
$1,374,231 |
D/D |
(45,042) |
72,363 |
|
-6% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-11 |
4 |
OE |
$10.36 |
$466,635 |
D/D |
45,042 |
117,405 |
|
- |
|
| Quart Barry D |
|
– • – |
2025-06-10 |
4 |
S |
$30.36 |
$249,316 |
D/D |
(8,212) |
12,546 |
|
5% |
|
| Quart Barry D |
|
– • – |
2025-06-10 |
4 |
OE |
$3.80 |
$31,206 |
D/D |
8,212 |
20,758 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-10 |
4 |
AS |
$30.46 |
$472,313 |
D/D |
(15,506) |
72,363 |
|
-5% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-10 |
4 |
OE |
$10.36 |
$160,642 |
D/D |
15,506 |
87,869 |
|
- |
|
| Quart Barry D |
|
– • – |
2025-06-09 |
4 |
S |
$30.26 |
$208,794 |
D/D |
(6,900) |
12,546 |
|
7% |
|
| Quart Barry D |
|
– • – |
2025-06-09 |
4 |
OE |
$3.80 |
$26,220 |
D/D |
6,900 |
19,446 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-09 |
4 |
AS |
$30.38 |
$313,491 |
D/D |
(10,319) |
72,363 |
|
-7% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-09 |
4 |
OE |
$10.36 |
$106,905 |
D/D |
10,319 |
82,682 |
|
- |
|
| Mccain Tracey L |
|
– • – |
2025-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
12,546 |
|
- |
|
| Cole G Bradley |
|
– • – |
2025-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
12,546 |
|
- |
|
| Levy Richard S |
|
– • – |
2025-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
17,373 |
|
- |
|
| Malley Thomas |
|
– • – |
2025-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
12,546 |
|
- |
|
| Popovits Kimberly J |
|
– • – |
2025-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
12,546 |
|
- |
|
| Quart Barry D |
|
– • – |
2025-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
12,546 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2025-06-03 |
4 |
AS |
$28.75 |
$437,316 |
D/D |
(15,211) |
32,546 |
|
-3% |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2025-06-03 |
4 |
OE |
$15.50 |
$235,771 |
D/D |
15,211 |
47,757 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-06-03 |
4 |
AS |
$28.80 |
$527,011 |
D/D |
(18,299) |
27,009 |
|
-3% |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-06-03 |
4 |
OE |
$18.00 |
$329,382 |
D/D |
18,299 |
45,308 |
|
- |
|
| Baker Julian |
|
– • – |
2025-06-03 |
4 |
A |
$0.00 |
$0 |
I/I |
16,794 |
2,738,816 |
|
- |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2025-06-03 |
4 |
AS |
$29.02 |
$800,778 |
D/D |
(27,594) |
9,415 |
|
-3% |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2025-06-03 |
4 |
OE |
$13.35 |
$368,380 |
D/D |
27,594 |
37,009 |
|
- |
|
430 Records found
|
|
Page 1 of 18 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (0.39%) 
